Is it a good company at a reasonable price? I own this stock and I bought it with my fooling around money. I plan to keep this stock. It would seem that it is currently cheap.
I own this stock of Well Health Technologies Corp (TSX-WELL, OTCQX-WHTCF). I was interested in this stock when I heard it was to acquire Toronto based MyHealth Centers. CanTech Letter says that TSX stock investors can buy today is Well Health (TSX-WELL), a company that operates in the health-tech space. WELL stock has already returned over 4,000% to shareholders since its initial public offering in April 2016. No Dividend. See CanTech Letter.
When I was updating my spreadsheet, I noticed that this stock has not done much since I bought it last year. I have a loss of 12%.
If you had invested in this company in December 2015, for $1,007.24 you would have bought 26 shares at $38.74 per share. In December 2025, after 10 years you would have received $247.17 in dividends. The stock would be worth $2,547.22. Your total return would have been $2,794.39. This would be a total return of 11.26% per year with 9.72% from capital gain and 1.54% from dividends.
| Cost | Tot. Cost | Shares | Years | Dividends | Stock Val | Tot Ret |
|---|---|---|---|---|---|---|
| $0.44 | $1,000.12 | 2,273 | 8 | $0.00 | $9,069.27 | $9,069.27 |
This stock has no dividends so no dividend yield and no Dividend Payout Ratios (DPR).
Debt Ratios are mostly fine, but they need to improve their Liquidity Ratio. The Long Term Debt/Market Cap Ratio for 2025 is good at 0.42 and currently at 0.45. The Liquidity Ratio for 2025 is low at 1.03 and far too low at 0.83 currently. If you added in Cash Flow after dividends, the ratios are still low at 1.37 and currently too low at 1.08. The Debt Ratio for 2025 is good at 1.98 and 1.94 currently. The Leverage and Debt/Equity Ratios for 2025 are fine at 2.43 and 1.22 and currently at 2.50 and 1.29.
| Type | Year End | Ratio Curr |
|---|---|---|
| Lg Term R | 0.42 | 0.45 |
| Intang/GW | 1.53 | 1.50 |
| Liquidity | 1.03 | 0.83 |
| Liq. + CF | 1.37 | 1.08 |
| Debt Ratio | 1.98 | 1.94 |
| Leverage | 2.43 | 2.50 |
| D/E Ratio | 1.22 | 1.29 |
The Total Return per Year is shown below for years of 5 to 8 to the end of 2025. Under the Capital Gain column is the portion of the Total Return attributable to capital gains. Under the Dividend column is the portion of the Total Return attributable to dividends. See chart below.
| From | Years | Div. Gth | Tot Ret | Cap Gain | Div. |
|---|---|---|---|---|---|
| 2020 | 5 | 0.00% | -13.10% | -13.10% | 0.00% |
| 2017 | 8 | 0.00% | 31.73% | 31.73% | 0.00% |
The 5-year low, median, and high median Price/Earnings per Share Ratios are coming up 0 because of too many earnings losses in the years of the past 5 years. The corresponding 7 year ratios are all negative and so useless. Therefore, I can do not P/E Ratio testing.
I also have Adjusted Earnings per Share (AEPS) data. The 5-year low, median, and high median Price/Earnings per Share Ratios are 12.86, 19.50 and 26.14. The corresponding 8 year ratios are 9.22, 13.74 and 18.26. The current ratio is 16.83 based on AEPS estimate for 2026 of $0.24 and a stock price of $4.04. This ratio is between the median and high ratios of the 10 year median ratios. This stock price testing suggests that the stock price is relatively reasonable but above the median.
I get a Graham Price of $4.30. The 10-year low, median, and high median Price/Graham Price Ratios are 0.71, 1.08 and 1.26. The current ratio is 0.94 based on a stock price of $4.04. The current ratio is between the low and median ratios of the 10 year median ratios. This stock price testing suggests that the stock price is relatively reasonable and below the median.
I get a 10-year median Price/Book Value per Share Ratio of 1.52. The current ratio is 1.18 based on Book Value of $867.8M, Book Value per Share of $3.42 and a stock price of $4.04. The current ratio is 22% below the 10 year median ratio. This stock price testing suggests that the stock price is relatively cheap.
I also have a Book Value per Share estimate for 2026 of $3.36. This produces a ratio of 1.20 with a Stock Price of $4.04 and a Book Value of $853M. This ratio is 20.8% below the 10 year median ratio. This stock price testing suggests that the stock price is relatively cheap.
I get a 10-year median Price/Cash Flow per Share Ratio of 11.39. The current ratio is 8.88 based on Cash Flow per Share estimate for 2026 of $0.45, Cash Flow of $115.5M and a stock price of $4.04. The current ratio is 22% below the 10 year median ratio. This stock price testing suggests that the stock price is relatively cheap.
I cannot do any dividend yield testing because this stock has no dividends.
The 10-year median Price/Sales (Revenue) Ratio is 2.02. The current ratio is 0.65 based on Revenue estimate for 2026 of $1590M, Revenue per Share of $6.26 and a Stock Price of $4.04. The current ratio is 68% below the 10 year median ratio. This stock price testing suggests that the stock price is relatively cheap.
Results of stock price testing is that the stock price is probably cheap. The P/S Ratio test is saying this and it is confirmed by the P/GP Ratio test. The other tests say that the stock price is cheap to reasonable.
When I look at analysts’ recommendations, I find Strong Buy (8), Buy (4), and Hold (1). The consensus would be a Strong Buy. The 12 month stock price consensus is $7.18 with a high of $8.25 and low of $5.00. The consensus stock price of $7.18 implies a total return of $77.72% all from capital gains based on a current stock price of $4.04.
There is really a divergence of opinion on this stock on Stock Chase and quite a number of entries for 2026. One analyst says Do Not Buy because it tries to be a technology company but has yet to prove it and he sold. Another says Buy because it is an exciting growth play and not an if story, but a when story. Jitendra Parashar on Motley Fool thinks this stock could be a strong multi-year growth winner. Amy Legate-Wolfe on Motley Fool says this stock is a strong buy and that it is expanding fast in clinics and healthcare software. The company put out a Press Release about its fourth quarter results for 2025. The company put out a Press Release about its first quarter of 2026..
Simply Wall Street via Yahoo Finance reviews this stock. It says to own WELL, you need to believe that its mix of clinics, digital tools, and AI can justify today's valuation despite forecast earnings declines and integration risk. It has two warnings on this stock of interest payments are not well covered by earnings; and earnings are forecast to decline by an average of 12% per year for the next 3 years.
WELL Health Technologies Corp is a practitioner-focused digital healthcare company. Its web site is here Well Health Technologies Corp.
The last stock I wrote about was about was Stingray Digital Group Inc (TSX-RAY.A, OTC-STGYF) ... learn more. The next stock I will write about will be BlackBerry Ltd (TSX-BB, NYSE-BB) ... learn more on Monday, August 3, 2026 around 5 pm.
This blog is meant for educational purposes only and is not to provide investment advice. I am not a licensed professional investment advisor. Before making any investment decision, you should always do your own research or consult an investment professional. I do research for my own edification and I am willing to share. I write what I think and I may or may not be correct.
See my site for an index to these blog entries and for stocks followed. I have three blogs. The first talks only about specific stocks and is called Investment Talk. The second one contains information on mostly investing and is called Investing Economics Mostly. My last blog is for my book reviews and it is called Non-Fiction Mostly. Follow me on Twitter. I am on Instagram. Or you can just Google #walktoronto spbrunner8166 to see my pictures.
Also, on my book blog I have put a review of the book The Golden Road by William Dalrymple learn more...